{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=2",
    "query": {
      "intervention": "Solution Vehicle",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T00:14:17.579Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04268069",
      "title": "Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "PL9643 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2020-02-14",
      "completion_date": "2020-10-05",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 4,
      "location_summary": "Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04268069"
    },
    {
      "nct_id": "NCT02653391",
      "title": "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fuchs' Corneal Endothelial Dystrophy (FCED)"
      ],
      "interventions": [
        {
          "name": "Part A Elamipretide 1.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part B Elamipretide 3.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part A Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-02",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 2,
      "location_summary": "Edgewood, Kentucky • Boston, Massachusetts",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653391"
    },
    {
      "nct_id": "NCT04792580",
      "title": "The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Graft-versus-host-disease",
        "Ocular Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard W Yee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-10-22",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 1,
      "location_summary": "Bellaire, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04792580"
    },
    {
      "nct_id": "NCT02061813",
      "title": "Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head Lice"
      ],
      "interventions": [
        {
          "name": "Abametapir Lotion 0.74% w/w",
          "type": "DRUG"
        },
        {
          "name": "Sodium Lauryl Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Saline 0.9%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Reddy's Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-01",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-07-26",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 1,
      "location_summary": "Paramus, New Jersey",
      "locations": [
        {
          "city": "Paramus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061813"
    },
    {
      "nct_id": "NCT03216902",
      "title": "A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma, Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical ultra-low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical medium dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "0.005% Latanoprost Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-07-25",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 12,
      "location_summary": "Artesia, California • Mission Hills, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216902"
    },
    {
      "nct_id": "NCT00721695",
      "title": "Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cataract Extraction"
      ],
      "interventions": [
        {
          "name": "OMS302",
          "type": "DRUG"
        },
        {
          "name": "OMS302-PE",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-05",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2014-07-18",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 4,
      "location_summary": "Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00721695"
    },
    {
      "nct_id": "NCT04806503",
      "title": "A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "UNR844",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "45 Years to 55 Years"
      },
      "enrollment_count": 234,
      "start_date": "2021-06-30",
      "completion_date": "2022-10-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 12,
      "location_summary": "Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Lake Villa",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806503"
    },
    {
      "nct_id": "NCT00755183",
      "title": "Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meibomian Gland Dysfunction"
      ],
      "interventions": [
        {
          "name": "testosterone ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "vehicle of testosterone ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-07",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00755183"
    },
    {
      "nct_id": "NCT01848041",
      "title": "Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blepharoptosis"
      ],
      "interventions": [
        {
          "name": "RVL-1201",
          "type": "DRUG"
        },
        {
          "name": "RVL-1201 Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RVL Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2013-05",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2021-11-26",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 1,
      "location_summary": "Morrow, Georgia",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848041"
    },
    {
      "nct_id": "NCT02693119",
      "title": "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leber's Hereditary Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "elamipretide (MTP-131) 1% topical ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle topical ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-03",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-09-10T00:14:17.579Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02693119"
    }
  ]
}